

CITATION REPORT

List of articles citing

Economic opportunities and challenges for pharmacogenomics

DOI: 10.1146/annurev.pharmtox.010909.105805
Annual Review of Pharmacology and Toxicology, 2010,
50, 423-37.

Source: <https://exaly.com/paper-pdf/49693251/citation-report.pdf>

Version: 2024-04-04

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
51	Real-world clinical effectiveness, regulatory transparency and payer coverage: three ingredients for translating pharmacogenomics into clinical practice. <i>Pharmacogenomics</i> , 2010 , 11, 657-60	2.6	16
50	Realities and expectations of pharmacogenomics and personalized medicine: impact of translating genetic knowledge into clinical practice. <i>Pharmacogenomics</i> , 2010 , 11, 1149-67	2.6	107
49	Individualizing pain therapy with opioids: The rational approach based on pharmacogenetics and pharmacokinetics. <i>European Journal of Pain Supplements</i> , 2010 , 4, 245-250		7
48	Dearth of clinically useful diagnostics limits growth of personalized medicine. <i>Expert Review of Clinical Pharmacology</i> , 2011 , 4, 527-9	3.8	
47	Perspectives for Globalized Natural Medicines. <i>Chinese Journal of Natural Medicines</i> , 2011 , 9, 1-6	2.8	13
46	Personalized medicine: are payers the weak link?. <i>Personalized Medicine</i> , 2011 , 8, 293-296	2.2	1
45	Pharmacogenetics and cost-effectiveness analysis: a two-way street. <i>Drug Discovery Today</i> , 2011 , 16, 873-7	8.8	8
44	Whole-genome resequencing in pharmacogenomics: moving away from past disparities to globally representative applications. <i>Pharmacogenomics</i> , 2011 , 12, 1717-28	2.6	21
43	Availability of pharmacogenetic and pharmacogenomic information in anticancer drug monographs in France: personalized cancer therapy. <i>Pharmacogenomics</i> , 2011 , 12, 681-91	2.6	4
42	Application of cost-effectiveness analysis to demonstrate the potential value of companion diagnostics in chronic myeloid leukemia. <i>Pharmacogenomics</i> , 2011 , 12, 411-21	2.6	11
41	Overcoming regulatory and economic challenges facing pharmacogenomics. <i>New Biotechnology</i> , 2012 , 29, 751-6	6.4	27
40	Challenges in the development and reimbursement of personalized medicine-payer and manufacturer perspectives and implications for health economics and outcomes research: a report of the ISPOR personalized medicine special interest group. <i>Value in Health</i> , 2012 , 15, 1162-71	3.3	100
39	Stratified medicine and reimbursement issues. <i>Frontiers in Pharmacology</i> , 2012 , 3, 181	5.6	14
38	The fourth hurdle of pharmacogenomics. <i>Pharmaceuticals Policy and Law</i> , 2012 , 14, 69-81		2
37	Pharmacogenetics and Pharmacogenomics of Chronic Kidney Disease Comorbidities and Kidney Transplantation. 2013 , 801-817		1
36	Clinical and economic challenges facing pharmacogenomics. <i>Pharmacogenomics Journal</i> , 2013 , 13, 378-88	3.5	45
35	Genomic medicine: new frontiers and new challenges. <i>Clinical Chemistry</i> , 2013 , 59, 158-67	5.5	50

34	Pharmacogenetics and pharmacogenomics: a bridge to individualized cancer therapy. <i>Pharmacogenomics</i> , 2013 , 14, 315-24	2.6	66
33	Pharmacogenomics in Cancer Therapeutics. 2013 , 89-116		
32	Clinical delivery of pharmacogenetic testing services: a proposed partnership between genetic counselors and pharmacists. <i>Pharmacogenomics</i> , 2013 , 14, 957-68	2.6	52
31	Personalizing health care: feasibility and future implications. <i>BMC Medicine</i> , 2013 , 11, 179	11.4	63
30	Impact of biomarkers on clinical trial risk. <i>Pharmacogenomics</i> , 2013 , 14, 1645-58	2.6	5
29	Economic Perspectives on Personalized Health Care and Prevention. <i>Forum for Health Economics and Policy</i> , 2013 , 16, S23-S52	0.9	11
28	Pharmacogenomics in the Era of Personal Genomics: A Quick Guide to Online Resources and Tools. 2013 , 187-211		1
27	When everyone is an orphan: against adopting a U.S.-styled orphan drug policy in Canada. <i>Accountability in Research</i> , 2013 , 20, 227-69	1.9	15
26	The quality of economic studies of cancer pharmacogenomics: a quantitative appraisal of the evidence. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2013 , 13, 597-611	2.2	6
25	The economic value of personalized medicine tests: what we know and what we need to know. <i>Genetics in Medicine</i> , 2014 , 16, 251-7	8.1	79
24	An index of barriers for the implementation of personalised medicine and pharmacogenomics in Europe. <i>Public Health Genomics</i> , 2014 , 17, 287-98	1.9	58
23	Clinical Pharmacogenetics. <i>Cancer Drug Discovery and Development</i> , 2014 , 803-821	0.3	
22	The application of economics concepts to stratified medicine--use of health economics data to support market access for stratified medicine interventions. <i>Journal of Medical Economics</i> , 2014 , 17, 305-11	2.4	5
21	Is individualized medicine more cost-effective? A systematic review. <i>Pharmacoeconomics</i> , 2014 , 32, 443-55	4.4	49
20	Clinical implementation of germ line cancer pharmacogenetic variants during the next-generation sequencing era. <i>Clinical Pharmacology and Therapeutics</i> , 2014 , 95, 269-80	6.1	53
19	Bridging genomics research between developed and developing countries: the Genomic Medicine Alliance. <i>Personalized Medicine</i> , 2014 , 11, 615-623	2.2	21
18	Application of genotype-guided cancer therapy in solid tumors. <i>Pharmacogenomics</i> , 2014 , 15, 79-93	2.6	17
17	Economic evaluations of personalized medicine: existing challenges and current developments. <i>Pharmacogenomics and Personalized Medicine</i> , 2015 , 8, 115-26	2.1	19

16	Genomics, personalized medicine, and supportive cancer care. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015 , 9-16	7.1	7
15	Genomic Medicine Today. 2015 , 9-25		
14	Economic viability of Stratified Medicine concepts: An investor perspective on drivers and conditions that favour using Stratified Medicine approaches in a cost-contained healthcare environment. <i>New Biotechnology</i> , 2016 , 33, 860-867	6.4	2
13	Economic evaluation of personalized medicine: a call for real-world data. <i>European Journal of Health Economics</i> , 2017 , 18, 1065-1067	3.6	8
12	Clinical Implementation of Pharmacogenomics for Personalized Precision Medicine: Barriers and Solutions. <i>Journal of Pharmaceutical Sciences</i> , 2017 , 106, 2368-2379	3.9	79
11	Using Cost-Effectiveness Analysis to Quantify the Value of Genomic-Based Diagnostic Tests: Recommendations for Practice and Research. <i>Genetic Testing and Molecular Biomarkers</i> , 2017 , 21, 705-716	1.6	5
10	The role of hospital pharmacists in the adoption and use of pharmacogenomics and precision medicine. <i>Personalized Medicine</i> , 2017 , 14, 27-35	2.2	16
9	Assessment of pharmacogenetic tests: presenting measures of clinical validity and potential population impact in association studies. <i>Pharmacogenomics Journal</i> , 2017 , 17, 386-392	3.5	30
8	Pharmacogenomics in Clinical Care and Drug Discovery. 2017 , 281-303		
7	On the readiness of physicians for pharmacogenomics testing: an empirical assessment. <i>Pharmacogenomics Journal</i> , 2018 , 18, 308-318	3.5	20
6	An Introduction to Pharmacogenomics and Personalized Medicine. 2015 , 1053-1065		1
5	Pharmacogenomics and Cancer Therapy: Somatic and Germline Polymorphisms. <i>Cancer Drug Discovery and Development</i> , 2014 , 255-272	0.3	
4	Pharmacogenomics and Personalized Medicine: Bridging Genetic Knowledge and Clinical Practice. 2014 , 1-16		
3	Clinical and economic issues complicating cost-effectiveness evaluation of orphan diseases. <i>The EuroBiotech Journal</i> , 2017 , 1, 132-137	1.5	
2	A systematic review on the cost effectiveness of pharmacogenomics in developing countries: implementation challenges.. <i>Pharmacogenomics Journal</i> , 2022 ,	3.5	0
1	Comparison of targeted vs. expanded pharmacogenomic testing: What are we missing?. 2023 ,		0